Older people, are underrepresented in randomised controlled trials of direct oral
anticoagulants (DOACs) for stroke prevention in atrial fibrillation (AF). The aim of this study …

Background Although older patients with atrial fibrillation are at heightened risk of
thromboembolic and bleeding events, their optimal treatment choice remains uncertain …

Objective To evaluate the efficacy and safety of oral anticoagulants for older adult patients
with atrial fibrillation (AF). Design Pairwise and network meta-analyses. Setting and …

Direct oral anticoagulants (DOACs) have been demonstrated to be more effective and safer
than vitamin-K antagonist (VKA) for stroke prevention in patients with nonvalvular atrial …

Background Oral anticoagulants are used for stroke prevention in patients with atrial
fibrillation, the most common cardiac arrhythmia in older adults. The aim of our study was to …

Background: Elderly population is known to be associated with polymedication,
comorbidities and altered drug pharmacokinetics. However, the most adequate oral …

Atrial fibrillation (AF) is the most common arrhythmia in clinical practice and its prevalence
increases with age. Few data are available about the clinical performance of direct oral …

The prevalence and embolic risk of atrial fibrillation (AF) increase with age. Vitamin K
antagonists (VKAs) or direct-acting oral anticoagulants (DOACs) reduce the risk of stroke or …

Background: The publication of high-quality observational studies (OSs) has fueled
reassessment of the treatment effects of direct oral anticoagulants (DOACs) in the elderly …

Direct oral anticoagulants (DOACs), previously also known as novel oral anticoagulants
(NOACs), have increased the therapeutic options for stroke prevention in atrial fibrillation …